KORU Medical Reports Q3 2026 Profitability and Increased Full-Year Guidance
KORU Medical (KRMD) reported strong third-quarter 2026 financial results, highlighted by its second consecutive quarter of profitability with a net income of $218,000. Net revenues rose 11.2% year-over-year to $11.6 million, driven primarily by growth in the recurring patient base and specialty pharmacy sales. Gross margins expanded significantly to 65.2%, benefiting from manufacturing efficiencies and lower tariff costs. The company demonstrated robust domestic core revenue growth of 31.6% on a reported basis. Following these results, KORU Medical raised its full-year gross margin guidance to 63%-64% and increased its year-end cash target to over $8 million. The company's long-term outlook is supported by a stable base of approximately 60,000 chronic immunoglobulin patients and ongoing clinical trial successes in subcutaneous therapy.
Topics: Financial Guidance Gross Margin Expansion Profitability Revenue Growth